Tuesday, October 18, 2022 9:36:19 PM
Yes Maverick, there is plenty of compelling narrative around the data that was not highlighted nor released during the presentations at NYAS and by KA and LL because the results are explosively outstanding and have therefore been reserved for the JA.
It is a no brainer that the JA results will include OS results of the 99 placebos whose mOS is about 24 months from randomization. This stunning mOS was obtained despite the fact that about 35 of the 99 were never-DCax-L-treated patients whose mOS was below 12 months, It is therefore a no brainer that the 64 mOS of the roughly 64 crossovers was well north of 24 months.
I am pretty sure therefore that we will see a very compelling JA but agree with you that this trial has been slower than molasses.
It is a no brainer that the JA results will include OS results of the 99 placebos whose mOS is about 24 months from randomization. This stunning mOS was obtained despite the fact that about 35 of the 99 were never-DCax-L-treated patients whose mOS was below 12 months, It is therefore a no brainer that the 64 mOS of the roughly 64 crossovers was well north of 24 months.
I am pretty sure therefore that we will see a very compelling JA but agree with you that this trial has been slower than molasses.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
